
Multiplmiyelom 'da umut vaat eden yeni tedavilere ulaşmak için lütfen tıklayınız.
80. Beksac
M, Haznedar R, Tuglular T, Ozdogu H, İ.Aydogdu, N.Konuk, G.Aysucak,
I.Kaygusuz, S.Karakus, E.Kaya, R.Ali, Z.Gulbas, G.Ozet, H.Goker, L.Undar.
Addition of thalidomide to oral melphalan/prednisone in patients with multiple
myeloma not eligible for transplantation: results of a randomized trial from
the Turkish Myeloma Study Group. Eur. J. Hematol. 2011 ;86(1):16-22.
87. Fayers PM, Palumbo A, Hulin
C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary
JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P,
Turesson I,
Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon
T. Thalidomide for previously untreated elderly patients with multiple myeloma:
meta-analysis of 1685 individual patient data from 6 randomized clinical
trials. Blood. 2011 4;118(5):1239-47.
88. Ludwig H, Beksac M,
Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach
J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M,
Leal da
Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T,
San-Miguel J,
Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Multiple myeloma
treatment strategies with novel agents in 2011: a European perspective.
Oncologist. 2011;16(4):388-403.
105.
Morabito F, Bringhen S, Larocca A, Wijermans P, Mateos MV, Gimsing P, Mazzone
C, Gottardi
D, Omedè P, Zweegman S, Lahuerta JJ, Zambello R, Musto P, Magarotto
V,
Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Turel AI,
Liberati
AM, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A,
Miguel JS,
Boccadoro M, Sonneveld P, Palumbo A, Offidani M. Bortezomib,
Melphalan,
Prednisone (VMP) versus Melphalan, Prednisone, Thalidomide (MPT) in
elderly
newly diagnosed Multiple Myeloma patients: A retrospective case-matched
study. Am J
Hematol. 2013 Nov 25. doi: 10.1002/ajh.23641. [Epub ahead of print]
PubMed
PMID: 24273190.
109. Richardson PG, Hungria VT, Yoon SS, Beksac
M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN,
Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H,
Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat
plus bortezomib and dexamethasone in previously treated multiple myeloma:
outcomes by prior treatment.Blood. 2016 Feb 11;127(6):713-21. doi:
10.1182/blood-2015-09-665018. Epub 2015 Dec 2. PMID:26631116
111. Terpos E, Kleber M, Engelhardt M, Zweegman
S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac
M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M,
Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; European
Myeloma Network guidelines for the management of multiple myeloma-related
complications.European Myeloma Network.Haematologica.
2015 Oct;100(10):1254-66. doi: 10.3324/haematol.2014.117176.PMID: 26432383
114. Richardson PG, Laubach JP, Lonial S, Moreau
P, Yoon SS, Hungria VT, Dimopoulos MA, Beksac M, Alsina M, San-Miguel
JF. Panobinostat: a novel pan-deacetylase inhibitor for the
treatment of relapsed or relapsed and refractory multiple myeloma.
Expert Rev Anticancer Ther. 2015;15(7):737-48. doi:
10.1586/14737140.2015.1047770. Epub 2015 Jun 7. Erratum in: Expert
Rev Anticancer Ther. 2015;15(9):1121. PMID:26051506
115. Lonial S, Dimopoulos M, Palumbo A,
White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H,
Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki
M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J,
Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple
Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. doi:
10.1056/NEJMoa1505654. Epub 2015 Jun 2.PMID:26035255
116. Beksac M, Waage A, Bringhen S,
Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Fıratlı-Tuğlular T,
Juliusson G, Turesson I, Palumbo A. Does
low-molecular-weight heparin influence the antimyeloma effects of thalidomide?
A retrospective analysis of data from the GIMEMA,
Nordic and Turkish myeloma study groups. Acta Haematol.
2015;133(4):372-80. doi: 10.1159/000370023. Epub 2015 Mar 24.PMID: 2582429
117. Iacobelli S, de Wreede LC, Schönland S,
Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin
L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg
K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet
L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. Impact
of CR before and after allogeneic and autologous transplantation in multiple
myeloma: results from the EBMT NMAM2000 prospective trial. Bone
Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015
Jan 26.PMID:25621805
118. Rajkumar SV, Dimopoulos MA, Palumbo
A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E,
Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S,
Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J,
Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H,
Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the
diagnosis of multiple myeloma. Lancet Oncol. 2014
Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.PMID: 25439696
119. Scheid C, Reece D, Beksac M, Spencer
A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK. Phase
2 study of dovitinib in patients with relapsed or refractory multiple myeloma
with or without t(4;14) translocation. Eur J Haematol. 2015
Oct;95(4):316-24. doi: 10.1111/ejh.12491. Epub 2015 Jan 22.PMID:25402977
120. San-Miguel JF, Hungria VT, Yoon SS, Beksac
M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN,
Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL,
Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi
H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen
W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn
SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F,
Richardson PG. Panobinostat
plus bortezomib and dexamethasone versus placebo plus bortezomib and
dexamethasone in patients with relapsed or relapsed and refractory multiple
myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol. 2014 Oct;15(11):1195-1206. doi: 10.1016/S1470-2045(14)70440-1.
Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. PMID:25242045
121. Lown RN, Philippe J, Navarro W, van Walraven
SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field
S, Yang H, Shaw BE; World Marrow Donor Association Clinical Working Group
Committee. Unrelated adult stem cell donor medical suitability:
recommendations from the World Marrow Donor Association Clinical Working Group
Committee. Bone Marrow Transplant. 2014 Jul;49(7):880-6. doi:
10.1038/bmt.2014.67. Epub 2014 Apr 7.PMID:24710563
122. Engelhardt M, Terpos E, Kleber M,
Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen
HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C,
Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F,
Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. European Myeloma Network recommendations on the evaluation
and treatment of newly diagnosed patients with multiple myeloma.
Haematologica. 2014 Feb;99(2):232-42. doi:
10.3324/haematol.2013.099358.PMID:24497560
123. Paul G. Richardson,1 Vânia T. M. Hungria,2 Sung-Soo Yoon,3 Meral Beksac,4 Meletios Athanasios Dimopoulos,5Ashraf Elghandour,6 Wieslaw W. Jedrzejczak,7 Andreas Guenther,8 Thanyaphong Na Nakorn,9 Noppadol Siritanaratkul,10 Robert L. Schlossman,1 Jian Hou,11 Philippe Moreau,12 Sagar Lonial,13 Jae Hoon Lee,14 Hermann Einsele,15 Monika Sopala,16 Bourras-Rezki Bengoudifa,16 Claudia Corrado,16 Florence Binlich,17 and Jesús F. San-Miguel18 “Panobinostat
plus bortezomib and dexamethasone in previously treated multiple myeloma:
outcomes by prior treatment” Received 2015 Sep 8; Accepted Blood. 2016 Feb 11; 127(6):
713–721. Prepublished online 2015 Dec 2. doi:
10.1182/blood-2015-09-665018
129.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka
I,Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X,
Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators..”Daratumumab, Bortezomib, and Dexamethasone for Multiple
Myeloma”. N Engl J Med. 2016 Aug 25;375(8):754-66.
130.
San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour
A,Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou
J,Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F,
Richardson PG. “Overall survival of patients with relapsed multiple myeloma
treated with panobinostat or placebo plus bortezomib and dexamethasone (the
PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial”. Lancet
Haematol. 2016 Oct 14. pii: S2352-3026(16)30147-8.
doi:10.1016/S2352-3026(16)30147-8. [Epub ahead of print] PubMed PMID: 27751707.
131. Raje
NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol
A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ,Nguyen TS, Cronier DM, Palumbo A. “Phase 2 study of
tabalumab, a human anti-B-cellactivating factor antibody, with bortezomib and
dexamethasone in patients with previously treated multiple myeloma”. Br J
Haematol. 2016 Dec 22. doi:10.1111/bjh.14483. [Epub ahead of print] PubMed
PMID: 28005265.
138. Dimopoulus MA, Lonial S, White D, Moreau P,
Palumbo A, San- Miguel
J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck
A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V,
Sheng J, Sy O, Katz J, Singhal A, Richardson P, “Elotuzumab plus
lenalidomide/dexamethasone for relapsed or refractory multiple myeloma:
ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and
tumour growth.” Br J Haem, 178(6):896-905, September 2017
139. San-Miguel JF, Hungria VTM, Yoon SS, Beksac
M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P,
Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG, “Panobinostat plus
bortezomib and dexamethasone: impact of dose intensity and administration
frequency on safety in the PANORAMA 1 trial.” Br J Haematol.179(1):66-74, October 2017
140. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H,
Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV,
O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M,
Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U,
Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D,
Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda
A, Kim JS, Durie BGM, “Natural history of relapsed myeloma, refractory to
immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG
study.”Leukemia, 31(11):2443-2448, Novenber 2017
147. Kumar
S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac
M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A “Propensity score matching analysis to
evaluate the comparative effectiveness of daratumumab versus real-world
standard of care therapies for patients with heavily pretreated and refractory
multiplemyeloma”.Leuk Lymphoma. ISSN:
1029-2403 2018 May 9 60:1, 163-171, DOI: 10.1080/10428194.2018.1459609
148. Weisel K, Sonneveld P, Spencer A, Beksac M, Rizzo M, Xu Y, Fahrbach K,
Gaudig M, Slavcev M, Dearden L, Lam A, “A Comparison of the Efficacy of
Immunomodulatory-free Regimens in Relapsed/Refractory Multiple Myeloma: A
Network Meta-analysis” Clinical Lymphoma Myeloma and Leukemia, ISSN: 1029-2403
Volume 18, Issue 3, 08 Nov 2018, Pages 163-173.e6 doi:
10.1016/j.clml.2017.12.011
150. Spencer A,
Lentzsch S, Weisel K, Avet-Loiseau H, M. Mark T, Spicka I, Masszi T, Lauri B,
Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, K. Nooka A, Quach H, Lee C,
Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M,
Beksac M, Ovilla R, Jo JC, Shin HJ,
Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M,
Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV, “Daratumumab Plus Bortezomib
And Dexamethasone Versus Bortezomib And Dexamethasone In Relapsed Or Refractory
Multiple Myeloma: Updated Analysis Of CASTOR” Haematologica 20 September 2018
haematol 2018. 103:12 2079-2087 194118; Doi:10.3324/haematol.2018.194118
152. Mohty M,
Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W,
Dimopoulos M, Stankovic S, Soledad Duran M, De Stefano V, Corso A, Kochkareva
Y, Laane E, Berthou C, Salwender H, Masliak Z, Peceliunas V, Willenbacher W,
Silva J, Louw V, Nemet D, Borbenyi Z, Abadi U, Pedersen RS, Feys C,
Thoret-Bauchet F, Boccadoro M, “Multiple Myeloma Treatment in Real-world
Clinical Practice: Results of a Prospective, Multinational, Noninterventional
Study” Clınıcal Lymphoma Myeloma & Leukemıa October 2018 V: 18 I: 10 P: E401-E419 DOI: 10.1016/j.clml.2018.06.018
160. Richardson, PG., Oriol, A., Beksac, M., Liberati, A.M., Galli, M.,
Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., Miguel, JS.,
Sunami, K., O’Gorman, P., Sonneveld, P.,
Robak, P., Semochkin, S., Schey, S., Yu, X., Doerr, T., Bensmaine, A., Biyukov,
T., Peluso, T., Zaki, M., Anderson, K., Dimopoulos, M., on behalf of the
OPTIMISMM trial investigators (2019) “Pomalidomide, bortezomib, and
dexamethasone for patients with relapsed or refractory multiple myeloma
previously treated with lenalidomide (OPTIMISMM): a randomised, open-label,
phase 3 trial.” Lancet Oncol. Jun 2019;20(6):781-794. doi:
10.1016/S1470-2045(19)30152-4.
161.Dimopoulos, M.A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R.,
Weisel, K.C., Goldschmidt, H., Maisnar, V., Moreau, P., Min C.K., Pluta, A.,
Chng, W.J., Kaiser, M., Zweegman, S., Mateos, M.V., Spencer, A., Iida, S.,
Morgan, G., Suryanarayan, K., Teng, Z.,
Skacel, T., Palumbo, A., Dash, A.B., Gupta, N., Labotka, R., Rajkumar, S.V.,
TOURMALINE-MM3 study group (2019) “Oral ixazomib maintenance following
autologous stem cell transplantation (TOURMALINE-MM3): a double-blind,
randomised, placebo-controlled phase 3 trial” Lancet. Jan 19 2019 393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4.
164. Kumar, S., Durie, B., Nahi, H., Vij, R., Dimopoulos, M.A.,
Kastritis, E., Terpos, E., Leleu, X., Beksac,
M., Goldschmidt, H., Hillengass, J., Su, Z., Hutton, B., Cameron, C., Khan,
I., Lam, A (2019) “Propensity score matching analysis to evaluate the
comparative effectiveness of daratumumab versus real-world standard of care
therapies for patients with heavily pretreated and refractory multiple myeloma”
LEUKEMIA & LYMPHOMA JAN 2 2019 ISSN: 1029-2403 Volume: 60 Issue:1
Pages:163-71 DOI:10.1080/10428194.2018.1459609
169. Attal
M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu
X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince
HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM
study group. “Isatuximab plus pomalidomide and low-dose dexamethasone versus
pomalidomide and low-dose dexamethasone in patients with relapsed and
refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label,
phase 3 study”. The Lancet. 2019 Nov 14. doi: 10.1016/S0140-6736(19)32556-5.
176. Landgren, O., Chari, A., Cohen, Y., Spencer, A., Voorhees, P., Estell,
J., Sandhu, I., Jenner, M., Williams, C., Cavo, M., van de Donk, N., Beksac,
M., Moreau, P., Goldschmidt, H., Kuppens, S., Bandekar, R., Clemens, P., Neff,
T., Heuck, C., Qi, M., Hofmeister, C., “Daratumumab Monotherapy for Patients
With Intermediate-risk or High-risk Smoldering Multiple Myeloma: A Randomized,
Open-label, Multicenter, Phase 2 Study (CENTAURUS)” Leukemia, DOI:
10.1038/s41375-020-0718-z Early Access:
FEB 2020
177. Cavo, M., Gay, F., Beksac, M., Pantani, L., Petrucci, M.T.,
Dimopoulos, M.A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., van der
Velden, V.H.J., Zamagni, E., Palumbo,
G., Patriarca, F., Montefusco, V., Galli, M., Maisnar, V., Gamberi, B.,
Hansson, M., Belotti, A., Pour, L., Ypma, P., Grasso, M., Croockewit, A.,
Ballanti, S., Offidani, M., Vincelli, I.D., Zambello, R., Liberati, A.M.,
Andersen, N.F., Broijl, A., Troia, R., Pascarella, A., Benevolo, G., Levin,
M.D., Bos, G., Ludwig, H., Aquino, S., Morelli, A.M., Wu, K.L., Boersma, R.,
Hajek, R., Durian, M., Borne, P.A., Toritto, T.C., Driessen, C., Specchia, G.,
Waage, A., Gimsing, P., Mellqvist, U.H., Kooy, M.M., Minnema, M., Mandigers,
C., Cafro, A.M., Palmas, A., Carvalho, S., Spencer, A., Boccadoro, E.,
Sonneveld, P., “Autologous
haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone,
with or without bortezomib–lenalidomide–dexamethasone consolidation therapy,
and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95):
a multicentre, randomised, open-label, phase 3 study” Lancet Haematol. 2020
Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30
182. Kaiser, M., Beksac, M.,
Gulbrandsen, N., Schjesvold, F., Hajek, R., Moreau, P., Arriba, F., Mateos,
M.V., West, S., Spencer, A., Rajkumar, S.V., Suryanarayan, K., Czorniak, M.,
Teng, M., Labotka, R., Dimopoulos, M.A., “Management of adverse events (AEs)
observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in
multiple myeloma (MM)” Clinical Lymphoma Myeloma and Leukemia, 2020, Volume 19,
Issue 10, Page e293,
https://doi.org/10.1016/j.clml.2019.09.481
188. Kaiser, M., Beksac, M., Gulbrandsen, N., Schjesvold, F., Hajek, R.,
Moreau, P., de la Fuente, F.D., Mateos, M.V., West, S., Spencer, A., Rajkumar,
S.V., Suryanarayan, K., Czorniak, M., Li, C., Teng, Z.Y., Labotka, R.,
Dimopoulos, M.A., “Adverse event management in the TOURMALINE-MM3 study of
post-transplant ixazomib maintenance in multiple myeloma” ANNALS OF HEMATOLOGY,
AUG 2020, Volume: 99 Issue: 8 Pages: 1793-1804 DOI: 10.1007/s00277-020-04149-5
189. Weisel, K., Spencer, A., Lentzsch, S., Avet-Loiseau, H., Mark, T.M.,
Spicka, I., Masszi, T., Lauri, B., Levin, M.D., Bosi, A., Hungria, V., Cavo, M., Lee, J.J., Nooka, A., Quach, H.,
Munder, M., Lee, C., Barreto, W., Corradini, P., Min, C.K., Chanan-Khan, A.A.,
Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J.C., Shin, H.J.,
Sonneveld, P., Casneuf, T., DeAngelis, T., Amin, H., Ukropec, J., Kobos, R.,
Mateos, M.V., “Daratumumab, bortezomib,
and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis
of CASTOR based on cytogenetic risk” Journal of Hematology & Oncology, 2020 Aug 20;13(1):115. doi:
10.1186/s13045-020-00948-5.